Hemophilia A Breakthrough as NEJM Publishes Landmark Results from XTEND-Kids Phase 3 Study
The New England Journal of Medicine (NEJM) has published full results from the XTEND-Kids phase 3 study on hemophilia A treatment, highlighting the efficacy,...
Sanofi’s Frexalimab Shows Promise in Reducing MS Nerve Cell Damage
Frexalimab, a CD40L monoclonal antibody developed by Sanofi, has shown significant potential in treating relapsing multiple sclerosis (MS) by reducing a key biomarker of...
Riliprubart Shows Promising Results in Treating Chronic Inflammatory Demyelinating Polyneuropathy
Sanofi’s complement C1s inhibitor, riliprubart, has shown encouraging efficacy and safety for participants with chronic inflammatory demyelinating polyneuropathy (CIDP) in an ongoing phase 2...
Cost Concerns: NICE Would Reject Sarclisa Even at Zero Cost, Says Sanofi
Cost concerns have driven Sanofi to strongly criticize National Institute for Health and Care Excellence's (NICE) decision not to recommend the use of Sarclisa...
Inactivated Polio Vaccines Production in Africa: Sanofi and Biovac Announce Strategic Partnership
Sanofi and Biovac have announced a partnership to produce inactivated polio vaccines in Africa. This agreement aims to support regional manufacturing capabilities and meet...
Therapy Setbacks and Advances: AstraZeneca’s Truqap, Sanofi’s New Partnership, and More
AstraZeneca faced a setback with its new breast cancer therapy, Truqap. The Capitello-290 trial, which evaluated Truqap in combination with chemotherapy for treating “triple-negative”...
Polyarticular juvenile idiopathic arthritis (pJIA) treatment has advanced with the Food and Drug Administration's (FDA) approval of Kevzara (sarilumab), developed by Regeneron and Sanofi,...
Heartburn Medication Zantac: Sanofi Settles 4,000 U.S. Lawsuits, Continues Delaware Defense
Sanofi has finalized a settlement to resolve approximately 4,000 personal injury lawsuits across the United States, excluding Delaware, concerning its heartburn medication, Zantac. These...
FDA Review Extended for Dupixent in COPD Treatment
The FDA has extended the priority review for Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD with type 2 inflammation. The...
Sanofi Expands Rare Disease Pipeline with Inhibrx Acquisition
Sanofi has completed its acquisition of Inhibrx, Inc., marking a significant expansion of its rare disease pipeline. This acquisition, finalized on May 30, 2024,...
